Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease

References

• Maseroli E, Vignozzi L. Testosterone and vaginal function. Sex Med Rev. 2020;8(3):379–392.
   PubMed Web of Science ®Google Scholar
• Gebhart JB, Rickard DJ, Barrett TJ, et al. Expression of estrogen receptor isoforms α and β messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol. 2001;185(6):1325–1330.
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, López CC, Alós L, et al. Oestrogen and progesterone receptors in the human vagina during the menstrual cycle, pregnancy and postmenopause. Maturitas. 1993;16(2):139–144.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Martel C, et al. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017;24(11):1246–1256.
   PubMed Web of Science ®Google Scholar
• Traish AM, Vignozzi L, Simon JA, et al. Role of androgens in female genitourinary tissue structure and function: implications in the genitourinary syndrome of menopause. Sex Med Rev. 2018;6(4):558–571.
   PubMed Web of Science ®Google Scholar
• Pérez-López FR, Vieira-Baptista P, Phillips N, et al. Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecol Endocrinol. 2021:1–6.
   PubMed Web of Science ®Google Scholar
• Phillips NA, Bachmann GA. Genitourinary syndrome of menopause: common problem, effective treatments. Cleve Clin J Med. 2018;85(5):390–398.
   PubMed Web of Science ®Google Scholar
• Rees M, Pérez-López FR, Ceasu I, EMAS, et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas. 2012;73(2):171–174.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(8):CD001500.
   PubMedGoogle Scholar
• Del Pup L. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients. Gynecol Endocrinol. 2012;28(9):740–745.
   PubMed Web of Science ®Google Scholar
• Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study. Maturitas. 2012;72(1):93–94.
   PubMed Web of Science ®Google Scholar
• Cano A, Estévez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy. Menopause. 2012;19(10):1130–1139.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Triratanachat S, Chaikittisilpa S, et al. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. Climacteric. 2013;16(3):347–355.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Ruan X, Prasauskas V, et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric. 2018;21(2):140–147.
   PubMed Web of Science ®Google Scholar
• Sánchez‐Rovira P, Hirschberg AL, Gil‐Gil M, et al. A phase ii prospective, randomized, double‐blind, placebo‐controlled and multicenter clinical trial to assess the safety of 0.005% estriol vaginal gel in hormone receptor‐positive postmenopausal women with early stage breast cancer in treatment with aromatase inhibitor in the adjuvant setting. Oncologist. 2020;25(12):e1846–1854.
   PubMed Web of Science ®Google Scholar
• Diedrich CM, Kastelein AW, Verri FM, et al. Effects of topical estrogen therapy on the vaginal microcirculation in women with vulvovaginal atrophy. Neurourol Urodyn. 2019;38(5):1298–1304.
   PubMed Web of Science ®Google Scholar
• Griesser H, Skonietzki S, Fischer T, et al. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas. 2012;71(4):360–368.
   PubMed Web of Science ®Google Scholar
• Liu JH, Bernick B, Mirkin S. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion. Expert Opin Drug Deliv. 2020;17(11):1573–1581.
   PubMed Web of Science ®Google Scholar
• Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019;26(4):431–453.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Bruyniks N, Princic N, et al. Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy. Curr Med Res Opin. 2014;30(1):143–148.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020;27(3):339–360.
   PubMed Web of Science ®Google Scholar
• Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis. 2011;15(4):263–267.
   PubMed Web of Science ®Google Scholar
• Bumphenkiatikul T, Panyakhamlerd K, Chatsuwan T, et al. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial. BMC Womens Health. 2020;20(1):173.
   PubMed Web of Science ®Google Scholar
• Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22(9):950–963.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2018;25(11):1339–1353.
   PubMed Web of Science ®Google Scholar
• Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452–461.
   PubMed Web of Science ®Google Scholar
• Pitsouni E, Grigoriadis T, Douskos A, et al. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2018;229:45–56.
   PubMed Web of Science ®Google Scholar
• Apperloo M, Midden M, van der Stege J, et al. Vaginal application of testosterone: a study on pharmacokinetics and the sexual response in healthy volunteers. J Sex Med. 2006;3(3):541–549.
   PubMed Web of Science ®Google Scholar
• Fernandes T, Pedro AO, Baccaro LF, et al. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study. Menopause. 2018;25(6):641–647.
   PubMed Web of Science ®Google Scholar
• Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837–847.
   PubMed Web of Science ®Google Scholar
• Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–161.
   PubMed Web of Science ®Google Scholar
• Herbenick D, Reece M, Hensel D, et al. Association of Lubricant Use with women's sexual pleasure, sexual satisfaction, and genital symptoms: a prospective daily diary study. J Sex Med. 2011;8(1):202–212.
   PubMed Web of Science ®Google Scholar
• Hickey M, Marino JL, Braat S, et al. A randomized, double-blind, crossover trial comparing a silicone-versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat. 2016;158(1):79–90.
   PubMed Web of Science ®Google Scholar
• Chen J, Geng L, Song X, et al. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(6):1575–1584.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Benedetto C, Campolo F, et al. Efficacy, tolerability and safety of a new medical device, Monurelle Biogel ® vaginal gel, in the treatment of vaginal dryness: a randomized clinical trial in women of reproductive age. Eur J Obstet Gynecol Reprod Biol. 2016;203:82–88.
   PubMed Web of Science ®Google Scholar
• Vale F, Rezende C, Raciclan A, et al. Efficacy and safety of a non-hormonal intravaginal moisturizer for the treatment of vaginal dryness in postmenopausal women with sexual dysfunction. Eur J Obstet Gynecol Reprod Biol. 2019;234:92–95.
   PubMed Web of Science ®Google Scholar
• Pieralli A, Bianchi C, Longinotti M, et al. Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms. Arch Gynecol Obstet. 2017;296(5):973–978.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Pitsouni E, Grigoriadis T, et al. CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial. Climacteric. 2021;24(2):187–193.
   PubMed Web of Science ®Google Scholar
• Bretas TLB, Issa MCA, Fialho SCVF, et al. Vaginal collagen I and III changes after carbon dioxide laser application in postmenopausal women with the genitourinary syndrome: a pilot study. Climacteric. 2021. doi: https://doi.org/10.1080/13697137.2021.1941850.
   Google Scholar
• Cruz VL, Steiner ML, Pompei LM, et al. Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2018;25(1):21–28.
   PubMed Web of Science ®Google Scholar
• Politano CA, Costa-Paiva L, Aguiar LB, et al. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause. Menopause. 2019;26(8):833–840.
   PubMed Web of Science ®Google Scholar
• Paraiso MFR, Ferrando CA, Sokol ER, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET Trial. Menopause. 2020;27(1):50–56.
   PubMed Web of Science ®Google Scholar
• Gaspar A, Brandi H, Gomez V, et al. Efficacy of Erbium: YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. Lasers Surg Med. 2017;49(2):160–168.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Levancini M, Russo E, et al. Long‐term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause. Climacteric. 2018;21(2):148–152.
   PubMed Web of Science ®Google Scholar
• Preti M, Vieira-Baptista P, Digesu GA, et al. The clinical role of laser for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. J Low Genit Tract Dis. 2019;23(2):151–160.
   PubMed Web of Science ®Google Scholar
• Vieira‐Baptista P. Better studies needed on LASER use in urinary incontinence. BJOG: Int J Obstet Gy. 2020;127(11):1347–1347.
   PubMed Web of Science ®Google Scholar
• Archer DF, Bernick BA, Mirkin S. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause. Expert Rev Clin Pharmacol. 2019;12(8):729–739.
   PubMed Web of Science ®Google Scholar
• Sánchez-Borrego R. Menopausal Hormone therapy. In: Pérez-López FR, editor. Postmenopausal diseases and disorders. p. 327–348. Spinger: Chen, Switzerland, 2019. https://doi.org/doi: https://doi.org/10.1007/978-3-030-13936-0, ISBN 978-3-030-13935-3
   Google Scholar
• Swanson SG, Drosman S, Helmond FA, et al. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause. 2006;13(6):917–925.
   PubMed Web of Science ®Google Scholar
• Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013;(6):CD009672.
   PubMed Web of Science ®Google Scholar
• Cui Y, Zong H, Yan H, et al. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta‐analysis. J Sexual Med. 2014;11(2):487–497.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Graham S, Lapane K, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26(7):800–807.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas. 2019;121:86–92.
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, Ospemifene Study Group, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–427.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93–100.
   PubMed Web of Science ®Google Scholar
• Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90(9):5226–5233.
   PubMed Web of Science ®Google Scholar
• Heard-Davison A, Heiman JR, Kuffel S. Genital and subjective measurement of the time course effects of an acute dose of testosterone vs. placebo in postmenopausal women. J Sex Med. 2007;4(1):209–217.
   PubMed Web of Science ®Google Scholar
• Achilli C, Pundir J, Ramanathan P, et al. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril. 2017;107(2):475–482.e15.
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Casson P, Lucas J, et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011;27(1):39–48.
   PubMed Web of Science ®Google Scholar
• Scheffers CS, Armstrong S, Cantineau AE, et al. Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev. 2015;1:CD011066.
   PubMedGoogle Scholar
• Mercier J, Morin M, Zaki D, et al. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: a single-arm feasibility study. Maturitas. 2019;125:57–62.
   PubMed Web of Science ®Google Scholar
• Mercier J, Morin M, Tang A, et al. Pelvic floor muscle training: mechanisms of action for the improvement of genitourinary syndrome of menopause. Climacteric. 2020;23(5):468–473.
   PubMed Web of Science ®Google Scholar
• Lee Y-K, Chung HH, Kim JW, et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors. Obstet Gynecol. 2011;117(4):922–927.
   PubMed Web of Science ®Google Scholar
• Advani P, Brewster AM, Baum GP, et al. A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy. J Cancer Surviv. 2017;11(4):477–485.
   PubMed Web of Science ®Google Scholar
• Pavlović RT, Janković SM, Milovanović JR, et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. Clin Breast Cancer. 2019;19(6):e731–e740.
   PubMed Web of Science ®Google Scholar
• Jain AL, Jamy O, Mullins J, et al. Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancer. Proc (Bayl Univ Med Cent)). 2020;33(3):331–335.
   PubMedGoogle Scholar
• Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer. JAMA Oncol. 2017;3(3):313–319.
   PubMed Web of Science ®Google Scholar
• Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause. 2020;27(5):526–534.
   PubMed Web of Science ®Google Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145(2):371–379.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. Menopause. 2018;25(6):596–608.
   PubMed Web of Science ®Google Scholar
• Reeder-Hayes K, Muss HB. Vaginal estrogens and aromatase inhibitors: how safe is safe enough?. JAMA Oncol. 2017;3(3):305–306.
   PubMed Web of Science ®Google Scholar
• Davis SR, Robinson PJ, Jane F, et al. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103(11):4146–4154.
   PubMed Web of Science ®Google Scholar
• Lønning PE. Concerns about methodology of a trial investigating vaginal health during aromatase inhibitor therapy for breast cancer. JAMA Oncol. 2017;3(8):1140.
   PubMedGoogle Scholar
• Barton DL, Sloan JA, Shuster LT, et al. Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(2):643–650.
   PubMed Web of Science ®Google Scholar
• Barton DL, Shuster LT, Dockter T, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(4):1335–1343.
   PubMed Web of Science ®Google Scholar
• Quick AM, Zvinovski F, Hudson C, et al. Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors. Support Care Cancer. 2020;28(8):3669–3677.
   PubMed Web of Science ®Google Scholar